ArticleCancer & metabolism2021
Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative
Article in Cancer & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Preoperative PET or PET/CT for malignant diagnosis of Gastrointestinal stromal tumors: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Review
- Imaging Strategies and Research Advances in Gastrointestinal Stromal Tumors.Current treatment options in oncology · 2026Review
- Article
- Molecular regulatory network of glycolytic reprogramming in hepatocellular carcinoma and its clinical implications.Biological procedures online · 2025Review
- PET/MR for predicting extranodal extension of head and neck cancer.Neuroradiology · 2025Article
- Article
- Prognostic Value of the Metabolic Response on SerialGut and liver · 2025Article
- 18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors.JAMA network open · 2025Article
- Gastric fundus leiomyoma: a rare case report.Frontiers in oncology · 2025Article
- Glycolysis in gastrointestinal stromal tumor: a brief overview.Neoplasia (New York, N.Y.) · 2024Review
- Predictive performance of [Quantitative imaging in medicine and surgery · 2024Article
- The impact of contour maps on estimating the risk of gastrointestinal stromal tumor recurrence: indications for adjuvant therapy: an analysis of the Kinki GIST registry.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- Malignant diagnosis and prognostic analysis of 89 GIST patients using preoperative FDG-PET.Scientific reports · 2023Article
- Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers.Frontiers in immunology · 2023Article
- Predictive value of intratumoral-metabolic heterogeneity derived fromFrontiers in oncology · 2023Article
- Early Prediction and Monitoring of Treatment Response in Gastrointestinal Stromal Tumors by Means of Imaging: A Systematic Review.Diagnostics (Basel, Switzerland) · 2022Review
- Value ofJournal of gastrointestinal oncology · 2022Article
- Clinical Perspectives forMetabolites · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThis study aimed to evaluate the prognostic value of pretreatment
methodsSixty-two localized GIST patients who underwent staging with
resultsPatients were followed up for a median of 42.0 months (range, 5.6-111.5). During the follow-up period, 13 patients (21.0%) experienced disease recurrence. In univariate analysis, tumor size (> 5 cm), mitotic count (> 5/high-power field), modified National Institutes of Health (NIH) consensus criteria, adjuvant imatinib treatment, SUVmax (≥ 7.04), MTV (≥ 50.76 cm
conclusionMTV and TLG are independent prognostic factors for predicting recurrence in patients with localized primary GIST. Patients with a high MTV or TLG are at risk for poor prognosis and should be closely observed for disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.